Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Söderlund, Johan ^a   Erhardt, Sophie ^a   Kast, Richard E ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; HYDROCORTISONE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; KYNURENINE; MARAVIROC; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TEMOZOLOMIDE; THYMIDINE KINASE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DRUG SAFETY; GLIOBLASTOMA; HERPES LABIALIS; HUMAN; LEUKOCYTE MIGRATION; NONHUMAN; PROGNOSIS; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; UPREGULATION; VIRUS REACTIVATION; DRUG ANTAGONISM; METABOLISM;

ACYCLOVIR; GLIOBLASTOMA; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; T-LYMPHOCYTES, REGULATORY;

EID: 77955210829     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-44     Document Type: Article

References (51)

1. Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Rønning P, Scheie D, Vik A, Meling TR. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010,
2. Seiz M, Krafft U, Freyschlag CF, Weiss C, Schmieder K, Lohr F, Wenz F, Thomé C, Tuettenberg J. Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. J Cancer Res Clin Oncol 2010,
3. Müller AC, Daya S. Acyclovir inhibits rat liver tryptophan-2,3-dioxygenase and induces a concomitant rise in brain serotonin and 5-hydroxyindole acetic acid levels. Metab Brain Dis 2008, 23:351-60. 10.1007/s11011-008-9095-4, 18665439.
4. Müller AC, Dairam A, Limson JL, Daya S. Mechanisms by which acyclovir reduces the oxidative neurotoxicity and biosynthesis of quinolinic acid. Life Sci 2007, 80:918-25. 10.1016/j.lfs.2006.11.031, 17174341.
5. Müller AC, Maharaj H, Maharaj DS, Daya S. Aciclovir protects against quinolinic-acid-induced oxidative neurotoxicity. J Pharm Pharmacol 2005, 57:883-8. 10.1211/0022357056442, 15969948.
6. Waziri A. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am 2010, 21:31-42. 10.1016/j.nec.2009.08.005, 19944964.
7. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, Lin Y, Dietz AB, Forsyth PA, Yong VW, Parney IF. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010, 12:351-65.
8. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, Salford LG, Sjögren HO, Widegren B. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 2000, 89:251-8. 10.1002/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5, 10861501.
9. Pellegatta S, Poliani PL, Stucchi E, Corno D, Colombo CA, Orzan F, Ravanini M, Finocchiaro G. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol 2010, 12:377-8.
10. Luptrawan A, Liu G, Yu JS. Dendritic cell immunotherapy for malignant gliomas. Rev Recent Clin Trials 2008, 3:10-21. 10.2174/157488708783330530, 18474011.
11. Klein L, Khazaie K, von Boehmer H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci USA 2003, 100:8886-91. 10.1073/pnas.1533365100, 166408, 12857946.
12. Walker LS. CD4+ CD25+ Treg: divide and rule?. Immunology 2004, 111:129-37. 10.1111/j.0019-2805.2003.01788.x, 1782405, 15027897.
13. Walker LS, Chodos A, Eggena M, Dooms H, Abbas AK. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 2003, 198:249-58. 10.1084/jem.20030315, 2194065, 12874258.
14. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006, 176:6752-61.
15. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003, 24:242-8. 10.1016/S1471-4906(03)00072-3, 12738417.
16. Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH, Young JW. IDO-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009, 114:555-63. 10.1182/blood-2008-11-191197, 2713474, 19465693.
17. Kong QF, Sun B, Wang GY, Zhai DX, Mu LL, Wang DD, Wang JH, Li R, Li HL. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Eur J Immunol 2009, 39:800-9. 10.1002/eji.200838729, 19283707.
18. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The IDO pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008, 181:5396-404.
19. Mahnke K, Bedke T, Enk AH. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol 2007, 250:1-13. 10.1016/j.cellimm.2008.01.004, 18313653.
20. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via IDO. J Clin Invest 2007, 117:2570-82. 10.1172/JCI31911, 1940240, 17710230.
21. Munn DH, Mellor AL. IDO and tumor-induced tolerance. J Clin Invest 2007, 117:1147-54. 10.1172/JCI31178, 1857253, 17476344.
22. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998, 273:14484-94. 10.1074/jbc.273.23.14484, 9603962.
23. Turner MS, Kane LP, Morel PA. Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J Immunol 2009, 183:4895-903. 10.4049/jimmunol.0901459, 19801514.
24. Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 2009, 182:2578-82. 10.4049/jimmunol.0803162, 19234151.
25. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The IDO pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008, 181:5396-404. 2614675, 18832696.
26. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Grohmann U, Puccetti P. SOCS3 drives proteasomal degradation of IDO and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci USA 2008, 105:20828-33. 10.1073/pnas.0810278105, 2634889, 19088199.
27. Belladonna ML, Puccetti P, Orabona C, Fallarino F, Vacca C, Volpi C, Gizzi S, Pallotta MT, Fioretti MC, Grohmann U. Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation 2007, 84:S17-20. 10.1097/01.tp.0000269199.16209.22, 17632406.
28. Belladonna ML, Volpi C, Bianchi R, Vacca C, Orabona C, Pallotta MT, Boon L, Gizzi S, Fioretti MC, Grohmann U, Puccetti P. Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol 2008, 181:5194-8.
29. Lietman PS. Acyclovir clinical pharmacology An overview. Am J Med 1982, 73:193-6. 10.1016/0002-9343(82)90089-4, 7048912.
30. Liao M, Pabarcus MK, Wang Y, Hefner C, Maltby DA, Medzihradszky KF, Salas-Castillo SP, Yan J, Maher JJ, Correia MA. Impaired dexamethasone-mediated induction of TDO in heme-deficient rat hepatocytes: translational control by a hepatic eIF2alpha kinase, the heme-regulated inhibitor. J Pharmacol Exp Ther 2007, 323:979-89. 10.1124/jpet.107.124602, 2881845, 17761498.
31. Carpentier AF, Meng Y. Recent advances in immunotherapy for human glioma. Curr Opin Oncol 2006, 18:631-6. 10.1097/01.cco.0000245321.34658.f4, 16988586.
32. Däubener W, MacKenzie CR. IFN-gamma activated IDO activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol 1999, 467:517-24.
33. MacKenzie CR, González RG, Kniep E, Roch S, Däubener W. Cytokine mediated regulation of interferon-gamma-induced IDO activation. Adv Exp Med Biol 1999, 467:533-9.
34. MacKenzie CR, Willberg CB, Däubener W. Inhibition of group B streptococcal growth by IFN gamma-activated human glioblastoma cells. J Neuroimmunol 1998, 89:191-7. 10.1016/S0165-5728(98)00138-6, 9726842.
35. Daubener W, Remscheid C, Nockemann S, Pilz K, Seghrouchni S, Mackenzie C, Hadding U. Anti-parasitic effector mechanisms in human brain tumor cells: role of interferon-gamma and tumor necrosis factor-alpha. Eur J Immunol 1996, 26:487-92. 10.1002/eji.1830260231, 8617321.
36. Daubener W, Pilz K, Seghrouchni Zennati S, Bilzer T, Fischer HG, Hadding U. Induction of toxoplasmostasis in a human glioblastoma by interferon gamma. J Neuroimmunol 1993, 43:31-8. 10.1016/0165-5728(93)90072-7, 8384636.
37. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009, 58:1627-34. 10.1007/s00262-009-0671-1, 19221744.
38. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GN. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008, 14:5166-72. 10.1158/1078-0432.CCR-08-0320, 18698034.
39. Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, Lowenstein PR, Castro MG. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One 2008, 3:e1983. 10.1371/journal.pone.0001983, 2291560, 18431473.
40. El Andaloussi A, Lesniak MS. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 2007, 83:145-52. 10.1007/s11060-006-9314-y, 17216339.
41. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS. Preferential migration of regulatory T cells mediated by glioma-secretedchemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008, 57:123-31. 10.1007/s00262-007-0336-x, 17522861.
42. Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ, Emmons RV, Witkiewicz AK. Expression of IDO in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009, 8:1930-4.
43. Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM, Leidenius MH. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 2009, 9:231. 10.1186/1471-2407-9-231, 2723126, 19604349.
44. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines blocked with chemotherapy. Cancer Immunol Immunother 2008, 57:123-31. 10.1007/s00262-007-0336-x, 17522861.
45. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009, 29:313-26. 10.1089/jir.2008.0027, 2755091, 19441883.
46. Kast RE. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. J Clin Pharm & Therapeutics 2010,
47. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002, 62:3347-50.
48. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 2008, 116:79-86. 10.1007/s00401-008-0359-1, 18351367.
49. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 2008, 10:10-8. 10.1215/15228517-2007-035, 2600830, 17951512.
50. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 2008, 359:539-41. 10.1056/NEJMc0804818, 2775501, 18669440.
51. Meije Y, Lizasoain M, García-Reyne A, Martínez P, Rodríguez V, López-Medrano F, Juan RS, Lalueza A, Aguado JM. Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clin Infect Dis 2010, 50:e73-6. 10.1086/653011, 20455691.